Echo Therapeutics appoints Alan Schoenbart as chief financial officer
Medical device company Echo Therapeutics (Nasdaq: ECTE) has appointed Alan Schoenbart as chief financial officer.
Mr Schoenbart is a senior executive with more than 30 years of experience in financial management, and took up the role on December 29.
Scott Hollander, president and chief executive of Echo Therapeutics, said: "Throughout his extensive career, Alan has consistently demonstrated exceptional business acumen in a variety of financial roles that will be key as we continue to build the corporate infrastructure necessary to support the advancement of our development pipeline. We are extremely pleased to welcome Alan to Echo's executive team and I'm confident that Alan will drive our focus on building value for Echo shareholders."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze